Eisai and Biogen to Discontinue Phase III Clinical Studies of Bace Inhibitor Elenbecestat in Early Alzheimer's Disease

Sep 13, 2019 18:43 JST

Source: Eisai

Discontinuation of studies based on Data Safety Monitoring Board recommendation

TOKYO, Sep 13, 2019 - (JCN Newswire) - Eisai Co., Ltd and Biogen Inc. today announced the decision to discontinue the Phase III clinical studies (MISSION AD1, AD2) on the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) in patients with early Alzheimer's disease (AD). The decision is based on the results of a safety review conducted by the Data Safety Monitoring Board (DSMB), which recommended to discontinue these trials due to an unfavorable risk-benefit ratio. Detailed data of these studies will be presented at future medical meetings.

Investigators are being informed of the decision and they will be contacting their study participants to discontinue the investigational treatment.

Dr. Lynn Kramer, Chief Clinical Officer, Neurology Business Group, Eisai Co., Ltd., said: "We would like to thank the patients and the families, as well as medical professionals, that participated in the MISSION AD studies. Without their contributions we would not be able to advance Alzheimer's disease research. We are very disappointed with the news, and intend to learn from these data and continue engaging with patients and investigators, to pursue the discovery of new medicines for Alzheimer's disease."

The Phase III clinical trial program for elenbecestat (MISSION AD) consisted of two global Phase III clinical studies with identical protocols, MISSION AD1 (Study 301) and MISSION AD2 (Study 302). Both studies were multicenter, placebo-controlled, double-blind, parallel-group Phase III clinical studies designed to assess the efficacy and safety of elenbecestat for treatment in a total of about 2,100 patients with mild cognitive impairment (MCI) or mild AD (collectively known as early AD) with confirmed amyloid pathology in the brain. Patients were randomized to receive either 50 mg of elenbecestat or placebo daily during the treatment period of 24 months, and the primary endpoint was the Clinical Dementia Rating Sum of Boxes (CDR-SB).

As part of this decision, the long-term extension of the Phase II clinical trial of elenbecestat (Study 202) will also be discontinued. This determination does not impact the program of the anti-amyloid beta (Abeta) protofibril monoclonal antibody BAN2401, and the Phase III Clarity AD trial of BAN2401 will continue.

Contact:

Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120

Source: Eisai
Sectors: BioTech

Related Press Release

Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy

February 16 2026 13:03 JST

Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China

February 10 2026 12:34 JST

Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan

February 06 2026 10:31 JST

FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review

January 26 2026 10:37 JST

Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time

January 21 2026 15:44 JST

Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan

January 13 2026 08:50 JST

Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China

January 06 2026 09:43 JST

Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year

December 11 2025 18:41 JST

"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List

December 09 2025 17:51 JST

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025

December 04 2025 17:36 JST

More Press release >>

Latest Press Release

Everest Medicines Shareholders Pass Resolutions Including Commercialization Service Agreement at EGM
Feb 25, 2026 21:59 JST

Toyota Launches New bZ4X Touring BEV Focused on Driving Performance and Spaciousness in Japan
Feb 25, 2026 21:58 JST

DOCOMO and Keio University Demonstrate World's First Stable, High-Fidelity Robot Teleoperation via Commercial 5G Using Low-Latency Slicing
Feb 25, 2026 21:01 JST

DOCOMO Successfully Demonstrates AI Application Operation Using Virtualized Radio Access Network (vRAN) Infrastructure

Feb 25, 2026 20:50 JST

DOCOMO Begins Commercial Deployment of Agentic AI System for Network Maintenance Using One of the World's Largest Datasets
Feb 25, 2026 20:40 JST

NEC Implements AI Code Review Service "Metabob," Reducing Technical Verification Time by Up to 66%
Feb 25, 2026 18:00 JST

Beisia Automates Supermarket Refrigerator Temperature Monitoring and Recording with Fujitsu's IoT Visualization Solution
Feb 25, 2026 12:00 JST

Galaxy Payroll Group Renews Five-Year Strategic Cooperation Agreement with NIKE China Holding HK Limited (Macau Branch)
Feb 25, 2026 04:35 JST

TANAKA to Provide Medals for the Tokyo Marathon 2026 That Represent All the Participants in the Event with Woven Lines
Feb 24, 2026 22:00 JST

Mitsubishi Shipbuilding Ships First Units of Systems for Marine Ammonia-Fueled Engines

Feb 24, 2026 20:07 JST

MHI Unveils "DIAVAULT," a Secure, High Performance Edge Data Center Platform
Feb 24, 2026 19:55 JST

Fujitsu expands Uvance for Finance offerings to accelerate DX across financial sector
Feb 24, 2026 11:23 JST

MHI Thermal Systems Establishes Local Subsidiary in India and Starts Operations
Feb 24, 2026 11:02 JST

Full Convertible Bond Conversion Removes Overhang and Signals Valuation Reassessment for Shoucheng Holdings
Feb 20, 2026 20:32 JST

Investee Companies Take the National Stage: Shoucheng Holdings' 'Capital+Scenario+Industry Chain' Strategy Validated, Entering the Value Realization Phase
Feb 20, 2026 20:06 JST

Hitachi Rail Invests C$30 Million in New Canadian Headquarters
Feb 20, 2026 12:20 JST

Toyota Launches New RAV4 (PHEV) in Japan
Feb 19, 2026 19:25 JST

Osaka Hospital launches project to safely utilize generative AI for healthcare workforce improvements
Feb 19, 2026 12:12 JST

MHI Machinery Systems Participates in Ramp Merging Support Demonstration Experiment for Autonomous Vehicles on the Tokyo Metropolitan Expressway
Feb 18, 2026 15:37 JST

IDC MarketScape names Hitachi Energy a Leader in Asset Performance Management for Worldwide Utilities
Feb 18, 2026 10:51 JST

More Latest Release >>